Related Experiment Videos
[166Dy]dysprosium/[166Ho]holmium in vivo generator
S V Smith1, N Di Bartolo, S Mirzadeh
1Biomedicine and Health Program, Australian Nuclear Science and Technology Organisation (ANSTO), New South Wales.
Summary
The novel in vivo generator system using 166Dy/166Ho-DTPA ensures the daughter nucleus 166Ho remains localized. Biodistribution studies confirm no significant loss of 166Ho from the complex in bone.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical chemistry
Background:
- A novel in vivo generator system utilizes the decay of 166Dy to deliver 166Ho to tissues.
- A critical concern is the potential translocation of the daughter nucleus (166Ho) after 166Dy decay.
Purpose of the Study:
- To investigate the in vitro and in vivo integrity of the [166Dy]Dy/166Ho-DTPA complex.
- To determine if daughter nucleus translocation occurs after beta- decay of 166Dy.
Main Methods:
- Evaluation of the [166Dy]Dy/166Ho-DTPA complex integrity.
- Biodistribution studies of [166Dy]Dy-DTPA in bone over a 20-hour period.
- Assessment of [166Dy]Dy-DTPA complex attached to HSA with increased residence time.
Main Results:
- No translocation of the daughter nucleus (166Ho) was observed following beta- decay of 166Dy.
- Biodistribution studies showed a constant ratio of 166Dy/166Ho in bone (+/- 7%) over 20 hours.
- Similar results were obtained when the [166Dy]Dy-DTPA complex was attached to HSA, indicating stable in vivo retention.
Conclusions:
- The [166Dy]Dy/166Ho-DTPA complex demonstrates integrity in vitro and in vivo.
- The in vivo generator system is effective, with no significant daughter nucleus translocation or loss from the complex.
- This supports the potential of the 166Dy/166Ho-DTPA system for targeted delivery of 166Ho in therapeutic applications.